Q-omics provides the consensus-scored SNX15 profile across patient tissues and cancer cell-line models. SNX15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNX15 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, SNX15 RNA expression shows 19,613 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where SNX15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX15 survival associations across molecular data types. SNX15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX15 RNA expression–survival associations across cancer types. High SNX15 expression shows unfavorable associations in KICH, CESC and UCEC, but favorable associations in HNSC, UCS and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for SNX15 RNA expression.
This table summarizes SNX15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNX15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX15 shows lower tumor expression in BRCA, THCA and UCEC and higher tumor expression in LIHC, HNSC and CHOL. The LIHC box plot shows higher SNX15 RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p < 0.001).
This table shows molecular features associated with SNX15 in patient tissues and cancer cell lines. In patient samples, SNX15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
